title: TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.
authors: T L
authors: TL
authors: Lasho
authors: A
authors: A
authors: Tefferi
authors: J D
authors: JD
authors: Hood
authors: S
authors: S
authors: Verstovsek
authors: D G
authors: DG
authors: Gilliland
authors: A
authors: A
authors: Pardanani
mesh_terms: D049109:Cell Proliferation / Q000187:drug effects; D041905:Erythroid Cells / Q000473:pathology*; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D011759:Pyrrolidines / Q000494:pharmacology*; D053628:Receptors, Thrombopoietin / Q000235:genetics; D013449:Sulfonamides / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D000096926:Benzenesulfonamides
chemical_list: D053614:Janus Kinase 2; D011759:Pyrrolidines; D053628:Receptors, Thrombopoietin; D013449:Sulfonamides; C082218:MPL protein, human; C528327:fedratinib; D000096926:Benzenesulfonamides; C507924:JAK2 protein, human